Research
Hormonal
Cry2 is critical for the circadian regulation of myogenic differentiation and fusion by maintaining Cyclin D1 expression and Tmem176b rhythmicity.
Cry2 helps coordinate the timing of muscle fiber fusion after injury. It ensures that cells don't exit the cell cycle too early and maintains the expression of genes needed for fibers to merge. Disruption of this clock component can lead to incomplete regeneration.
ModerateSupportsMEDIUM confidence
These defects in differentiation and regeneration processes in Cry2 KO animals and cell lines were attributed to a detrimental and premature exit from the cell cycle due to inhibited Cyclin D1 expression (28).
Why this rating
Based on Cry2 KO mice and cell lines; mechanism is detailed but requires validation in human physiological models.
Source
Molecular clocks, satellite cells, and skeletal muscle regeneration
Ryan E. Kahn et al. · American Journal of Physiology-Cell Physiology · 2023
DOI 10.1152/ajpcell.00073.2023
narrative_reviewCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Skeletal muscle regeneration efficiency is time-of-day dependent, with injury occurring during the active phase (when satellite cell BMAL1 expression peaks) resulting in enhanced repair compared to injury during the inactive phase.Moderate
- The molecular clock component BMAL1 is required for satellite cell proliferation and the metabolic transition from oxidative to glycolytic energy sources during early muscle regeneration.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →